Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

EP: 1.Exploring the Landscape Surrounding Light Chain Amyloidosis

EP: 2.Expert Perspectives on Differentiating Signs and Symptoms in AL Amyloidosis Diagnosis

EP: 3.Exploring Diagnostic Approaches for Patients with Light Chain Amyloidosis

EP: 4.Current Treatment Landscape for AL Amyloidosis

EP: 5.Unmet Needs and Treatment Considerations in Managing AL Amyloidosis

Now Viewing

EP: 6.Treatment Strategies Using Monoclonal Antibodies in AL Amyloidosis

EP: 7.Optimizing Treatment Management Strategies in AL Amyloidosis with CD38-Directed mAbs

EP: 8.Addressing Challenges in Managing AL Amyloidosis with Cardiac Involvement

EP: 9.The Role of Cardiac Staging in Patients with AL Amyloidosis

EP: 10.Novel Treatment Approaches with mAbs Targeting Amyloid Deposits: Insights from VITAL

EP: 11.AFFIRM-AL: Birtamimab in Patients with Mayo Stage IV AL Amyloidosis

EP: 12.Expert Insights on Pooled Safety Data from the PRONTO and VITAL trials

EP: 13.The Potential Role of CAR T Therapy in AL Amyloidosis

EP: 14.NEXICART-1: Safety and Efficacy of NXC-201 in AL Amyloidosis

EP: 15.Looking Ahead: Future Perspectives on AL Amyloidosis

This is a video synopsis/summary of a Peer Exchange involving Heather Landau, MD; Vaishali Sanchorawala, MD; and Jeffrey Zonder, MD.

Panelists discuss the use of monoclonal antibodies in light chain (AL) amyloidosis, emphasizing the transformative impact of the ANDROMEDA trial. Anti-CD38 antibodies, both in combination with chemotherapy and as single agents in relapse, exhibit impressive response rates that exceed those in multiple myeloma. Data on isatuximab and elotuzumab also show promise, with potential later-line use. Belantamab mafodotin, a B-cell maturation antigen–directed antibody, reveals high response rates but comes with ocular toxicity challenges.

This discussion introduces the concept of antibodies targeting protein fibrils and highlights the evolving treatment landscape and promising avenues with monoclonal antibodies, particularly anti-CD38 antibodies, which offer new possibilities for improved therapeutic outcomes in AL amyloidosis.

Video synopsis is AI-generated and reviewed by OncLive^® editorial staff.